drugset / Trial / NCT01313065

Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors

NCT01313065

Phase 1 Completed 42 enrolled Vaccinex Inc. PPD Development, LP · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in patients with advanced solid tumors. The escalation part of the study will determine the maximum tolerated dose (MTD).

Timeline

Start
2011-01
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Pepinemab Monoclonal antibody 0.3 mg/kg Intravenous
Subject Pepinemab Monoclonal antibody 20 mg/kg Intravenous

Indications